Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J To Seek Remicade Rights Amid Pending Schering-Plough/Merck Merger

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck and Schering argue the merger does not constitute “change of control” for Remicade and Simponi under initial J&J agreement.

You may also be interested in...



Merck And J&J Settle Remicade Dispute By Redrawing The Map

Johnson & Johnson Inc. and Merck & Co. Inc. settled their two-year dispute over Remicade (infliximab) and its successor Simponi (golimumab) April 15, avoiding an arbitrator's decision by striking a revised agreement under which each will retain some territorial rights to the drugs

Merck And J&J Settle Remicade Dispute By Redrawing The Map

Rather than let an arbitration panel decide the fate of two anti-TNF drugs, Merck surrenders many territories but holds onto Europe.

Merck And J&J Settle Remicade Dispute By Redrawing The Map

Rather than let an arbitration panel decide the fate of two anti-TNF drugs, Merck surrenders many territories but holds onto Europe.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel